Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 4, 2014, Pages 777-786

  Li, Zheng ^a   Qing, Yi ^a   Guan, Wei ^a   Li, Mengxia ^a   Peng, Yu ^a   Zhang, Shiheng ^a   Xiong, Yanli ^a   Wang, Dong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Advanced non small cell lung cancer; APE1; ERCC1; Individualized chemotherapy; TUBB3

Indexed keywords

ANTINEOPLASTIC AGENT; APEX1 PROTEIN, HUMAN; BRCA1 PROTEIN; CISPLATIN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; PACLITAXEL; TUBB3 PROTEIN, HUMAN; TUBULIN; TUMOR MARKER;

CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; DNA REPAIR; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENDONUCLEASES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84925546448     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2562-1     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90. doi:10.3322/caac.20107
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249. doi:10.3322/caac.20006
3. Wang D, Luo M, Kelley MR (2004) Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 3(6):679-686
4. Koukourakis MI, Giatromanolaki A, Kakolyris S, Sivridis E, Georgoulias V, Funtzilas G, Hickson ID, Gatter KC, Harris AL (2001) Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. Int J Radiat Oncol Biol Phys 50(1):27-36
5. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, Investigators IB (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983-991. doi:10.1056/NEJMoa060570
6. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D (2007) ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol Off J Am Soc Clin Oncol 25(33):5172-5179. doi:10.1200/JCO.2007.11.8547
7. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO 18(3):504-509. doi:10.1093/annonc/mdl430
8. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 25(10):1247-1254. doi:10.1200/JCO.2006.08.1844
9. Kennedy RD, Quinn JE, Johnston PG, Harkin DP (2002) BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360(9338):1007-1014. doi:10.1016/S0140-6736(02)11087-7
10. Leng XF, Chen MW, Xian L, Dai L, Ma GY, Li MH (2012) Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with nonsmall cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res CR 31:25. doi:10.1186/1756-9966-31-25
11. Kim D, Jung W, Koo JS (2011) The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci 26(3):352-359. doi: 10.3346/jkms.2011.26.3.352
12. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N (2007) ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2(10):902-906. doi:10.1097/JTO.0b013e318155a637
13. Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR (2013) Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 31(19):2404-2412. doi:10.1200/JCO.2012.46.9783
14. Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, Filipits M, Chen Y, Kutok JL, Weaver DT, Ward BE, Soria JC (2012) Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol Off J Eur Soc Med Oncol ESMO 23(9):2245-2252. doi:10.1093/annonc/mdr624
15. Kalogeraki A, Karvela-Kalogeraki I, Tamiolakis D, Petraki P, Saridaki Z, Tzardi M (2014) ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples. Revista portuguesa de pneumologia 20(4):200-207. doi:10.1016/j.rppneu.2013.11.002
16. Seve P, Dumontet C (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9(2):168-175. doi:10.1016/S1470-2045(08)70029-9
17. Tang SC (2008) Predictive markers of tubulin-targeting agents in breast cancer. Clin Breast Cancer 8(Suppl 2):S79-S84
18. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H (2009) Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64(3):326-333. doi:10.1016/j.lungcan.2008.09.002
19. Seve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, Perol M, Lafanechere L, Penet A, Peiller EL, Dumontet C (2005) Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clini Cancer Res Off J Am Assoc Cancer Res 11(15):5481-5486. doi:10.1158/1078-0432.CCR-05-0285
20. Tsuchida Y, Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37(1):1-3. doi:10.1002/mpo.1154
21. Vilmar A, Garcia-Foncillas J, Huarriz M, Santoni-Rugiu E, Sorensen JB (2012) RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer 75(3):306-312. doi:10.1016/j.lungcan.2011.08.016
22. Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS (2009) APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 66(3):298-304. doi:10.1016/j.lungcan.2009.02.019
23. Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J (2012) ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 7(4):663-671. doi:10.1097/JTO.0b013e318244bdd4
24. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala MA, Jimenez U, Diz P, Barneto I, Macias JA, de Las Penas R, Catot S, Isla D, Sanchez JM, Ibeas R, Lopez-Vivanco G, Oramas J, Mendez P, Reguart N, Blanco R, Taron M (2009) Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 4(5):e5133. doi:10.1371/journal.pone.0005133
25. Olaussen KA, Fouret P, Kroemer G (2007) ERCC1-specific immunostaining in non-small-cell lung cancer. N Engl J Med 357(15):1559-1561. doi:10.1056/NEJMc072007
26. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Vinolas N, Paz-Ares L, Lopez-Vivanco G, Munoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 25(19):2747-2754. doi:10.1200/JCO.2006.09.7915
27. Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10(3):194-204. doi:10.1038/nrc2803
28. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M (2010) Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther 9(5):1339-1348. doi:10.1158/1535-7163.MCT-09-0679
29. Kamath K, Wilson L, Cabral F, Jordan MA (2005) BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280(13):12902-12907. doi:10.1074/jbc.M414477200
30. Ando K, Hirao S, Kabe Y, Ogura Y, Sato I, Yamaguchi Y, Wada T, Handa H (2008) A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res 36(13):4327-4336. doi: 10.1093/nar/gkn416
31. Fishel ML, Kelley MR (2007) The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 28(3-4):375-395. doi:10.1016/j.mam.2007.04.005
32. Tell G, Fantini D, Quadrifoglio F (2010) Understanding different functions of mammalian AP endonuclease (APE1) as a promising tool for cancer treatment. Cell Mol Life Sci CMLS 67(21):3589-3608. doi:10.1007/s00018-010-0486-4
33. Tell G, Damante G, Caldwell D, Kelley MR (2005) The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid Redox Signal 7(3-4):367-384. doi:10.1089/ars.2005.7.367
34. Al-Attar A, Gossage L, Fareed KR, Shehata M, Mohammed M, Zaitoun AM, Soomro I, Lobo DN, Abbotts R, Chan S, Madhusudan S (2010) Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br J Cancer 102(4):704-709. doi:10.1038/sj.bjc.6605541
35. Sheng Q, Zhang Y, Wang R, Zhang J, Chen B, Wang J, Zhang W, Xin X (2012) Prognostic significance of APE1 cytoplasmic localization in human epithelial ovarian cancer. Med Oncol 29(2):1265-1271. doi:10.1007/s12032-011-9931-y
36. Rosell R, Mendez P, Isla D, Taron M (2007) Platinum resistance related to a functional NER pathway. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2(12):1063-1066. doi:10.1097/JTO.0b013e31815ba2a1
37. Kinsella TJ (2009) Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics. Semin Oncol 36(2 Suppl 1):S42-S51. doi:10.1053/j.seminoncol.2009.02.004
38. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8(3):193-204. doi:10.1038/Nrc2342
39. McNeil EM, Melton DW (2012) DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res 40(20):9990-10004. doi:10.1093/nar/gks818
40. Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM (2010) Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair 9(7):745-753. doi:10.1016/j.dnarep.2010.03.010
41. Niedernhofer LJ, Bhagwat N, Wood RD (2007) ERCC1 and non-small-cell lung cancer. N Engl J Med 356(24):2538-2540. doi:10.1056/NEJMc070742
42. Roth JA, Carlson JJ (2011) Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung cancer 12(6):393-401. doi:10.1016/j.cllc.2011.04.005
43. Zhou SF (2007) ERCC1 and non-small-cell lung cancer. N Engl J Med 356(24):2540
44. Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, Suehisa H, Kobayashi N, Aoe M, Yoshino T, Kiura K, Date H (2008) ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 59(3):377-384. doi:10.1016/j.lungcan.2007.08.025
45. Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B (2008) ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 8:97. doi:10.1186/1471-2407-8-97
46. Jordan MA, Kamath K (2007) How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7(8):730-742
47. Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2(1):1-17
48. Seve P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T (2007) Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res Off J Am Assoc Cancer Res 13(3):994-999. doi:10.1158/1078-0432.CCR-06-1503